Silexion Therapeutics (SLXN) Competitors $0.89 -0.03 (-2.87%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock SLXN vs. FGEN, RANI, GRCE, ALXO, PULM, COEP, SXTC, IPA, MRNS, and ALLKShould you be buying Silexion Therapeutics stock or one of its competitors? The main competitors of Silexion Therapeutics include FibroGen (FGEN), Rani Therapeutics (RANI), Grace Therapeutics (GRCE), ALX Oncology (ALXO), Pulmatrix (PULM), Coeptis Therapeutics (COEP), China SXT Pharmaceuticals (SXTC), ImmunoPrecise Antibodies (IPA), Marinus Pharmaceuticals (MRNS), and Allakos (ALLK). These companies are all part of the "pharmaceutical products" industry. Silexion Therapeutics vs. Its Competitors FibroGen Rani Therapeutics Grace Therapeutics ALX Oncology Pulmatrix Coeptis Therapeutics China SXT Pharmaceuticals ImmunoPrecise Antibodies Marinus Pharmaceuticals Allakos Silexion Therapeutics (NASDAQ:SLXN) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, community ranking, profitability and risk. Do analysts rate SLXN or FGEN? Silexion Therapeutics currently has a consensus price target of $5.00, suggesting a potential upside of 464.59%. FibroGen has a consensus price target of $10.00, suggesting a potential upside of 3,141.49%. Given FibroGen's higher possible upside, analysts plainly believe FibroGen is more favorable than Silexion Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00FibroGen 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has higher valuation and earnings, SLXN or FGEN? Silexion Therapeutics has higher earnings, but lower revenue than FibroGen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilexion TherapeuticsN/AN/A$260KN/AN/AFibroGen$7.00M4.46-$284.23M-$0.10-3.09 Does the media refer more to SLXN or FGEN? In the previous week, FibroGen had 2 more articles in the media than Silexion Therapeutics. MarketBeat recorded 3 mentions for FibroGen and 1 mentions for Silexion Therapeutics. Silexion Therapeutics' average media sentiment score of 1.89 beat FibroGen's score of 0.72 indicating that Silexion Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Silexion Therapeutics Very Positive FibroGen Positive Is SLXN or FGEN more profitable? Silexion Therapeutics has a net margin of 0.00% compared to FibroGen's net margin of -67.66%. Company Net Margins Return on Equity Return on Assets Silexion TherapeuticsN/A N/A -249.43% FibroGen -67.66%N/A -36.17% Does the MarketBeat Community believe in SLXN or FGEN? FibroGen received 345 more outperform votes than Silexion Therapeutics when rated by MarketBeat users. However, 66.67% of users gave Silexion Therapeutics an outperform vote while only 58.81% of users gave FibroGen an outperform vote. CompanyUnderperformOutperformSilexion TherapeuticsOutperform Votes266.67% Underperform Votes133.33% FibroGenOutperform Votes34758.81% Underperform Votes24341.19% Which has more volatility and risk, SLXN or FGEN? Silexion Therapeutics has a beta of 0.12, meaning that its stock price is 88% less volatile than the S&P 500. Comparatively, FibroGen has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Do insiders & institutionals have more ownership in SLXN or FGEN? 10.9% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 72.7% of FibroGen shares are held by institutional investors. 33.0% of Silexion Therapeutics shares are held by company insiders. Comparatively, 3.1% of FibroGen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryFibroGen beats Silexion Therapeutics on 7 of the 13 factors compared between the two stocks. Get Silexion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLXN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLXN vs. The Competition Export to ExcelMetricSilexion TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.70M$3.12B$5.61B$8.62BDividend YieldN/A1.56%5.28%4.17%P/E RatioN/A32.9027.1419.96Price / SalesN/A466.20411.83157.63Price / Cash1.46168.6838.2534.64Price / Book-0.133.427.064.69Net Income$260K-$72.35M$3.23B$248.14M7 Day Performance-3.90%7.27%2.67%2.39%1 Month Performance-11.34%17.53%8.82%6.05%1 Year PerformanceN/A-17.27%31.44%13.60% Silexion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLXNSilexion TherapeuticsN/A$0.89-2.9%$5.00+464.6%N/A$7.70MN/A0.00N/AUpcoming EarningsGap DownFGENFibroGen4.5706 of 5 stars$0.32+2.0%$10.00+3,029.9%-72.7%$32.28M$7.00M-0.26570News CoverageRANIRani Therapeutics2.0115 of 5 stars$0.57+2.5%$9.40+1,537.3%-85.7%$32.19M$1.20M-0.54110GRCEGrace Therapeutics2.7771 of 5 stars$3.16+6.4%$12.00+279.7%N/A$32.04MN/A-2.72N/AHigh Trading VolumeALXOALX Oncology2.7001 of 5 stars$0.58-0.1%$3.30+470.2%-93.6%$30.90MN/A-0.1940News CoverageAnalyst RevisionPULMPulmatrix0.42 of 5 stars$8.44-5.1%N/A+334.2%$30.81M$1.92M-3.2020Positive NewsGap DownCOEPCoeptis Therapeutics1.3964 of 5 stars$8.75-2.2%N/A+49.6%$30.75M$62.87K-1.512SXTCChina SXT Pharmaceuticals0.489 of 5 stars$1.94-7.2%N/A-77.6%$30.71M$1.82M0.0090Short Interest ↑Gap DownIPAImmunoPrecise Antibodies2.6639 of 5 stars$0.67-0.4%$4.00+497.2%-41.1%$30.65M$24.00M-0.8680News CoverageOptions VolumeMRNSMarinus Pharmaceuticals2.2026 of 5 stars$0.55-0.2%$4.79+771.6%-64.8%$30.32M$30.99M-0.22110ALLKAllakos3.9277 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190 Related Companies and Tools Related Companies FibroGen Alternatives Rani Therapeutics Alternatives Grace Therapeutics Alternatives ALX Oncology Alternatives Pulmatrix Alternatives Coeptis Therapeutics Alternatives China SXT Pharmaceuticals Alternatives ImmunoPrecise Antibodies Alternatives Marinus Pharmaceuticals Alternatives Allakos Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLXN) was last updated on 6/12/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silexion Therapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Silexion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SLXN Stock Free SLXN Stock Alerts